PDE4A and COVID-19: Several groups also proposed PDE4 inhibitors for COVID-19 management [3,146,147] based on the assumption that the upstream inhibition of inflammatory pathways via increased cAMP levels may outclass single anti-cytokine drugs, especially once multiple cytokines are massively released [148].